Takeaways: This notice of allowance shores up Anixa’s IP moat around its AMHR2‑targeted ovarian cancer vaccine and aligns Canada with its existing US patent protection. ...
Takeaways: BeOne Medicines has cleared the key reimbursement hurdles in Canada for TEVIMBRA + gemcitabine/cisplatin as the first publicly funded first-line immunotherapy for recurrent/metas...
Takeaways: Quaebec’s reimbursement of Vanflyta is a pivotal step toward pan‑Canadian access for a high‑value, biomarker‑targeted AML therapy. Market-wise, public funding acr...
Takeaways: Ontario’s reimbursement of BRAFTOVI is a meaningful win for Pfizer and a strong signal for precision oncology adoption in Canada. It should accelerate uptake in a biomarker-defined me...
Takeaways Blenrep’s pCPA negotiations are an important step toward broader Canadian access to a new multiple myeloma option, especially because the drug is being positio...
For decades, oncology innovation has focused primarily on developing more effective treatments for advanced disease. Today, however, the industry is beginning to shift toward a new frontier: detecting...
Precision medicine is often defined by breakthrough therapies and targeted treatments, but behind many of these advances lies a less visible yet increasingly essential component: companion diagnostics...
The pharmaceutical industry has long occupied a complex position in public perception, celebrated for life saving innovation yet frequently criticized for pricing practices, transparency concerns, and...
Takeaways: Bosaya and Vevzuo, layered on top of other recent denosumab biosimilar launches, should accelerate formulary switches and tender competition, strengthen Biocon’s credi...
